

IOME OF SIDNEY KIMMEL MEDICAL COLLEGE



Introduction

- Constipation is commonly encountered in patients admitted to the hospital, with a variety of possible treatments to choose from
- Docusate (Colace) is often prescribed to treat constipation, though evidence suggests it has limited efficacy
- Utilizing an ineffective medication adds to patients' pill burden, health care costs, and may delay the use of effective medications with downstream consequences

Research Objective

To determine if reducing access to docusate decreases the administration of docusate and increases the use of evidence-based bowel regimens in a cost-effective manner

Methods

- Docusate was removed from from >500 admission order sets at 12 hospitals within the Jefferson Health system on April 4th, 2023
- Docusate was replaced with more evidence-based bowel regimens (polyethylene glycol [PEG], senna, etc)
- We reviewed administration data of the following medications in inpatient locations at 90 days pre- and post-intervention:
 - Docusate
 - Bisacodyl
 - Senna
 - PEG
 - Methylnaltrexone
 - Enemas
 - Suppositories
- We also reviewed pricing data of each of the medications studied in order to extrapolate the cost effects

Cancel Colace: A Quality Improvement Approach to Improving Bowel Regimens Using More Evidence Based Medications

Elizabeth Klingensmith¹, Jeffrey M. Riggio, MD, MS, FACP², Dana M. Jordan PharmD, BCPS³, Alan A. Kubey MD, FACP^{2,4} (1) Sidney Kimmel Medical College, Philadelphia, PA (2) Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA (3) Department of Pharmacy, Thomas Jefferson University Hospital, Philadelphia, PA (4) Department of Internal Medicine, Mayo Clinic, Rochester, MN

Results

Docusate dosing decreased from 65,691 to 34,407 in the post-intervention period (Confidence Interval [CI]: -47.5%-48.5%, p<0.0001) (Figure 1)

- Corresponds to 126,874 fewer doses per year
- Cost savings (not including pharmacy or nursing time) of \$7,421.55/year (Figure 2)





Table: Percentage Change in Doses	
Medication	% Chan
Docusate	
PEG	
Senna	
Bisacodyl	
Enemas	
Methylnaltrexone	

Administered nge in Administration -48% 4% 6% 6% -2% 21%



Conclusions

- Docusate has limited efficacy and adds to the medication burden of patients
- decreased the amount of docusate administered to of evidenced-based medications
- Limitations
 - trends in prescribing
- Implications
 - treatments
 - increase in annual cost

References

Fakheri RJ, Volpicelli FM. Things we do for no reason: prescribing docusate for constipation in hospitalized adults. J Hosp Med. 2019;14(2):110-113

Removing docusate from admission ordering sets and replacing with evidence-based regimens significantly patients over the study period and increased the use

• 90 day pre- and post-intervention analysis may not have been long enough to reveal true

• These results can be used to guide further interventions to improve use of evidence-based

• Further study, possibly with a longer analysis period, is required to understand the net